Patent Infringement: Delhi High Court Restrains Zydus From Manufacturing Biologic Similar To 'Nivolumab' Cancer Drug

The Delhi High Court has restrained Zydus from manufacturing a biologic similar to Nivolumab, a cancer drug, citing patent infringement. This interim injunction was granted in a patent infringement suit, indicating the court's recognition of the patent holder's rights over the innovator drug. The decision underscores the critical importance of intellectual property protection in the pharmaceutical sector, especially for complex biologic drugs, to incentivize research and development of life-saving medicines.